4SC gets Phase IIa boost
This article was originally published in Scrip
Executive Summary
Shareholders responded positively to preliminary Phase IIa data unveiled by 4SC, the German drug discovery company, relating to its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release, in inflammatory bowel disease (IBD). The company reported that the exploratory, open-label, single-arm Phase IIa ENTRANCE study met its primary endpoint of significantly increasing the response rate in corticosteroid-dependent IBD patients to 88.5% against an average placebo response across published benchmark clinical trials of approximately 20%.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.